BR112022023112A2 - Moduladores de enpp1 e usos dos mesmos - Google Patents
Moduladores de enpp1 e usos dos mesmosInfo
- Publication number
- BR112022023112A2 BR112022023112A2 BR112022023112A BR112022023112A BR112022023112A2 BR 112022023112 A2 BR112022023112 A2 BR 112022023112A2 BR 112022023112 A BR112022023112 A BR 112022023112A BR 112022023112 A BR112022023112 A BR 112022023112A BR 112022023112 A2 BR112022023112 A2 BR 112022023112A2
- Authority
- BR
- Brazil
- Prior art keywords
- modulators
- enpp1
- quinazolines
- quinoline
- methods
- Prior art date
Links
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 title abstract 3
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 title abstract 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003246 quinazolines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Radar Systems Or Details Thereof (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063024937P | 2020-05-14 | 2020-05-14 | |
| PCT/US2021/032249 WO2021231726A1 (en) | 2020-05-14 | 2021-05-13 | Enpp1 modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022023112A2 true BR112022023112A2 (pt) | 2023-01-17 |
Family
ID=76250495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022023112A BR112022023112A2 (pt) | 2020-05-14 | 2021-05-13 | Moduladores de enpp1 e usos dos mesmos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230183188A1 (https=) |
| EP (1) | EP4149927A1 (https=) |
| JP (1) | JP2023526050A (https=) |
| KR (1) | KR20230012535A (https=) |
| CN (1) | CN116348451A (https=) |
| AR (1) | AR122090A1 (https=) |
| AU (1) | AU2021273001A1 (https=) |
| BR (1) | BR112022023112A2 (https=) |
| CA (1) | CA3178372A1 (https=) |
| IL (1) | IL298169A (https=) |
| MX (1) | MX2022014126A (https=) |
| TW (1) | TW202208336A (https=) |
| WO (1) | WO2021231726A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202208337A (zh) * | 2020-05-04 | 2022-03-01 | 美商佛拉斯托醫療公司 | Ｅｎｐｐ１之亞胺基硫烷酮抑制劑 |
| JP2023549738A (ja) | 2020-10-30 | 2023-11-29 | １シーバイオ， インコーポレイテッド | エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼ－１（ｅｎｐｐ１）阻害物質及びそれらの使用 |
| EP4433455A1 (en) * | 2021-11-15 | 2024-09-25 | VIR Biotechnology, Inc. | Enpp1 modulators and uses thereof |
| US20260049084A1 (en) * | 2022-05-13 | 2026-02-19 | Gossamer Bio Services, Inc. | Enpp1 modulators and products and uses thereof |
| US12397517B2 (en) | 2023-10-23 | 2025-08-26 | Unik World Industrial Co., Ltd. | Vehicle-mounted air compressor |
| WO2025117697A1 (en) * | 2023-11-29 | 2025-06-05 | Riboscience Llc | 7-aza bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| WO2017066964A1 (en) * | 2015-10-22 | 2017-04-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
| EA201991556A1 (ru) * | 2016-12-22 | 2020-01-23 | Мавуфарма, Инк. | Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции |
| TW201920104A (zh) * | 2017-08-31 | 2019-06-01 | 美商馬愈法瑪公司 | 外核苷酸焦磷酸酶-磷酸二酯酶1(enpp-1)抑制劑及其用途 |
| WO2019177971A1 (en) * | 2018-03-12 | 2019-09-19 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
| KR20220068243A (ko) * | 2019-09-23 | 2022-05-25 | 난징 젱시앙 파마슈티칼스 컴퍼니 리미티드 | 포스포디에스테라제 억제제 및 용도 |
| TW202208337A (zh) * | 2020-05-04 | 2022-03-01 | 美商佛拉斯托醫療公司 | Ｅｎｐｐ１之亞胺基硫烷酮抑制劑 |
-
2021
- 2021-05-13 CA CA3178372A patent/CA3178372A1/en active Pending
- 2021-05-13 EP EP21729757.1A patent/EP4149927A1/en not_active Withdrawn
- 2021-05-13 IL IL298169A patent/IL298169A/en unknown
- 2021-05-13 CN CN202180060383.XA patent/CN116348451A/zh active Pending
- 2021-05-13 AU AU2021273001A patent/AU2021273001A1/en not_active Abandoned
- 2021-05-13 JP JP2022568810A patent/JP2023526050A/ja active Pending
- 2021-05-13 MX MX2022014126A patent/MX2022014126A/es unknown
- 2021-05-13 KR KR1020227043581A patent/KR20230012535A/ko not_active Withdrawn
- 2021-05-13 TW TW110117372A patent/TW202208336A/zh unknown
- 2021-05-13 BR BR112022023112A patent/BR112022023112A2/pt not_active Application Discontinuation
- 2021-05-13 WO PCT/US2021/032249 patent/WO2021231726A1/en not_active Ceased
- 2021-05-13 AR ARP210101325A patent/AR122090A1/es not_active Application Discontinuation
-
2022
- 2022-11-16 US US17/988,575 patent/US20230183188A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW202208336A (zh) | 2022-03-01 |
| MX2022014126A (es) | 2023-04-10 |
| AU2021273001A1 (en) | 2022-12-15 |
| EP4149927A1 (en) | 2023-03-22 |
| AR122090A1 (es) | 2022-08-10 |
| IL298169A (en) | 2023-01-01 |
| CA3178372A1 (en) | 2021-11-18 |
| US20230183188A1 (en) | 2023-06-15 |
| CN116348451A (zh) | 2023-06-27 |
| WO2021231726A1 (en) | 2021-11-18 |
| JP2023526050A (ja) | 2023-06-20 |
| KR20230012535A (ko) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023112A2 (pt) | Moduladores de enpp1 e usos dos mesmos | |
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| BR112022011651A2 (pt) | Degradadores de irak e usos dos mesmos | |
| BR112022012410A2 (pt) | Degradadores smarca e usos dos mesmos | |
| CO2021013339A2 (es) | Degradadores de stat y usos de los mismos | |
| BR112022018678A2 (pt) | Degradadores de mdm2 e usos dos mesmos | |
| CL2018001361A1 (es) | Inhibidores éster de acc y usos de los mismos | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| BR112022004802A2 (pt) | Moduladores de il-17a e usos dos mesmos | |
| BR112021006392A2 (pt) | moduladores da alfa-1 antitripsina | |
| CL2017001050A1 (es) | Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| BR112018016433A2 (pt) | inibidores de heteroarila de pad4 | |
| EP3877371A4 (en) | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | |
| CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| CL2018001360A1 (es) | Inhibidores triazol de acc y usos de los mismos | |
| MX2021005171A (es) | Inhibidores de cinasas reguladas por señal extracelular (erk) y usos de los mismos. | |
| PT3781561T (pt) | Moduladores de enzimas modificadoras de metilo, composições e usos dos mesmos | |
| BR112018011709A2 (pt) | inibidores bicíclicos de pad4 | |
| BR112018070133A2 (pt) | dispersão, uso desta e método para a inativação fotodinâmica de micro-organismos | |
| EA033395B1 (ru) | Ингибиторы индоламин-2,3-диоксигеназы и способы их применения | |
| BR112023020781A2 (pt) | Moduladores de cbl-b e usos dos mesmos | |
| BR112015032595A2 (pt) | inibidores de ido | |
| BR112015023760A2 (pt) | compostos e composições terapêuticas | |
| MX2019008435A (es) | Inhibidores selectivos de jak1. | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |